Results 91 to 100 of about 29,245 (221)

Combination of approved chemotherapeutics and natural products for topoisomerase II targeting: efficacy and safety in cancer therapy

open access: yesHolistic Integrative Oncology
Cancer is characterized by abnormal cell growth and remains a leading global cause of death despite advances in conventional therapies. Limitations such as lack of selectivity, cytotoxic side effects, and multidrug resistance underscore the need for ...
Ali H. El-Far   +5 more
doaj   +1 more source

Design and synthesis of novel rigid dibenzo[b,f]azepines through ring closure technique as promising anticancer candidates against leukaemia and acting as selective topoisomerase II inhibitors and DNA intercalators. [PDF]

open access: yesJ Enzyme Inhib Med Chem, 2023
El-Behairy MF   +8 more
europepmc   +1 more source

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, restores blood–brain barrier integrity in a human stem cell‐based model of ischaemic stroke

open access: yesBritish Journal of Pharmacology, EarlyView.
Ischaemic stroke is characterised by acute cerebrovascular occlusion and blood–brain barrier (BBB) breakdown. Our results indicated that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) ameliorated the loss of BBB integrity, changed the morphology of brain endothelial cells, increased the level of basement membrane and ...
Anikó Szecskó   +14 more
wiley   +1 more source

Pathophysiological and Molecular Features of DXd ADC‐Related Interstitial Pneumonitis in Cynomolgus Monkeys

open access: yesCancer Science, EarlyView.
An interstitial lung disease model for DXd antibody‐drug conjugates was established in cynomolgus monkeys by weekly dosing of a non‐targeting DXd ADC. Integrated analysis of bronchoalveolar lavage fluid–derived extracellular vesicle proteomics and lung single‐cell RNA sequencing reveals cell‐type‐resolved molecular features of DXd ADC‐related lung ...
Kazuyoshi Kumagai   +5 more
wiley   +1 more source

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy. [PDF]

open access: yesCancers (Basel), 2021
Matias-Barrios VM   +7 more
europepmc   +1 more source

circMAN1A2 as an Isoform‐Resolved Circular RNA Hub in Cancer

open access: yesCancer Science, EarlyView.
circMAN1A2 as an isoform‐resolved circular RNA hub in cancer. circMAN1A2 is generated by back‐splicing of MAN1A2 pre‐mRNA, with alternative circularization producing multiple isoforms, including the predominant circMAN1A2(2–5). Its mechanistic interfaces include miRNA‐associated regulation, RBP binding/proteostasis control, BSJ‐mediated RNA–RNA pairing,
Hanyu Shang   +4 more
wiley   +1 more source

Proteostasis of organelles in aging and disease

open access: yesThe FEBS Journal, EarlyView.
Cells rely on regulated proteostasis mechanisms to keep their internal compartments functioning properly. When these mechanisms fail, damaged proteins accumulate, disrupting organelles, such as the nucleus, mitochondria, endoplasmic reticulum, Golgi, and lysosomes, as well as membraneless organelles, such as stress granules, processing bodies, the ...
Yara Nabawi   +5 more
wiley   +1 more source

Human APOBEC3G suppresses homologous recombination and LIG4‐independent end joining in DNA double‐strand break repair

open access: yesThe FEBS Journal, EarlyView.
Chromosomal DNA double‐strand breaks (DSBs) are repaired by homologous recombination and nonhomologous end joining (NHEJ). Recent work has additionally established theta‐mediated end‐joining (TMEJ) as a mechanism for DSB joining. Cells lacking NHEJ and TMEJ can repair DSBs in a homology‐dependent manner.
Shinta Saito   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy